Forbion
Drug Discovery · Venture Capital
$2.7Braised in 2 rounds
5open roles in its portfolio
3investments
5countries with offices
Overview
Forbion is a European venture capital firm dedicated to life sciences, backing biotech companies that develop groundbreaking therapies. It invests from seed and early-stage rounds through growth financings, and has added a BioEconomy strategy for sustainable nutrition and health solutions. The firm was founded in 2006 through a buyout of the life sciences team of ABN AMRO and is headquartered in Naarden, the Netherlands, with an office in Munich.
Investor profile
Venture capitalInvestments
3
3 of them startups
Hiring now
3
5 open roles
Focusshare of its companies
Biotechnology 100%Health Care 67%
Where its companies are
Switzerland 33%Italy 33%
Stage of its companies
Series B 100%
Its companies, the freshest money firstAll 3 investments
AAVantgardeSeries B $141M · 12 mo ago · led a round · 2 roles
Orbis MedicinesSeries A $97.2M · 22 mo ago · led a round · 1 role
Noema PharmaSeries B · 23 mo ago · 1 role
Co-investorscompanies they hold together
Sources: 3 rounds in the press that name it
Growth
Hiring Momentum
24/100
Hiring freeze
Open positions
2
0 opened / 1 closed in 30 days
Median time-to-fill
57 days
faster than 24% of the market
ATS activity
Every ~5 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Administrative
33% ▲
Education
33% ▲
Early Careers
33% ▲
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors

KfW CapitalVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK
Read more
Report
Forbion Bioeconomy Fund I Reaches €200 Million Hard Cap
Forbion announced that its Forbion BioEconomy Fund I has closed at its hard cap of €200 million, marking one of the most significant dedicated bioeconomy funds in Europe. The fund focuses on biotechnology-driven solutions that support planetary health and
Read more
Report
Forbion taps ex-Dyne CEO Josh Brumm as general partner, plans Boston office
Brumm stepped down from Dyne in March to pursue opportunities in healthcare investing.
Read more
Report
Offices
Where the company hires and what each office is for
Cities
8
Hiring now
1
Countries
5
Busiest office
Naarden
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Naarden
Netherlands
HQ
Naarden, Netherlands
2 open roles 3 posted in 90 days 10-50 est. staff
hires for Administrative, Education
PO Box 5187, 1410 AD Naarden
Amsterdam
Netherlands
Regional office
Amsterdam, Netherlands
Munich
Germany
Regional office
Munich, Germany
Boston
United States
Regional office
Boston, US
Dresden
Germany
Regional office
Dresden, Germany
Cambridge
United Kingdom
Regional office
Cambridge, UK
Horgen
Switzerland
Regional office
Numab
Oss
Netherlands
Regional office
Citryll - Oss

Sofinnova Partners